Please login to the form below

Not currently logged in

Sun Pharma recalls antidepressant in US

Withdraws more than 40,000 bottles of venlafaxine hydrochloride
Sun Pharma

India-based Sun Pharmaceutical Industries is to recall more than 40,000 bottles of an antidepressant after the drug was discovered to have problems dissolving in the body.

US regulator the FDA announced the recall of venlafaxine hydrochloride last week, stating: “Stability results found the product did not meet the drug release dissolution specifications.”

Sun now has to withdraw 26,530 bottles of 30 pills of the depression treatment and 14,597 bottles containing 90 pills.

The FDA classed the recall as class II, meaning that this is a situation in which use of or exposure to a product may cause temporary or medically reversible adverse health consequences. However, the probability of serious adverse health consequences is remote compared to class I.

Venlafaxine hydrochloride is part of the serotonin-norepinephrine reuptake inhibitor (SNRI) class of medicines to treat people with major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder.

Sun Pharma's product is is a generic version of Pfizer/Wyeth's Effexor XR, which itself faced a recall earlier this year after one bottle was reported to contain a heart drug.

This is the latest in a series of setbacks for Sun Pharma in the US. During 2014 so far the company has faced a recall of chemotherapy drug gemcitabine due to sterility issues, while in January the company withdrew 2,528 bottles of its generic version of metformin.

The company has also come under criticism for its operations in India, with the FDA banning imports from a plant in Karkhadi and sending a warning letter detailing how employees deleted records of batch failures.

Article by
Thomas Meek

14th July 2014

From: Sales, Regulatory, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...